FrancophonIA/ELRC3.0 huggingface dataset:
English: If patients with HIV1 infection need to stop taking emtricitabine or tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.
Estonian: Kui HIV-1 infektsiooniga patsientidel on vaja katkestada emtritsitabiini või tenofoviiri võtmine või muuta nende annust, peavad nad võtma emtritsitabiini või tenofoviirdisoproksiili sisaldavaid ravimeid eraldi.
English: Because Emtricitabine/Tenofovir disoproxil Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Emtricitabine/Tenofovir disoproxil Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the Agency's view was that, as for Truvada, the benefits of Emtricitabine/Tenofovir disoproxil Zentiva outweigh the identified risks and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Truvada korral, ületab ravimi Emtricitabine/Tenofovir disoproxil Zentiva kasulikkus sellega kaasnevad riskid ja seda võib ELis kasutada.
English: For more information about using Emtricitabine/Tenofovir disoproxil Zentiva, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Emtricitabine/Tenofovir disoproxil Zentiva kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Zentiva?
Estonian: Mis meetmed võetakse, et tagada ravimi Emtricitabine/Tenofovir disoproxil Zentiva ohutu ja efektiivne kasutamine?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Zentiva have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Emtricitabine/Tenofovir disoproxil Zentiva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Healthcare professionals will also receive a brochure and reminder card to hand out to individuals receiving the medicine for pre-exposure prophylaxis.
Estonian: Tervishoiutöötajad saavad ka voldiku ja meelespea, mille nad annavad patsientidele, kes kasutavad ravimit kokkupuute-eelseks profülaktikaks.
English: Emtricitabine/Tenofovir disoproxil Zentiva is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Ravimit Emtricitabine/Tenofovir disoproxil Zentiva kasutatakse koos vähemalt ühe muu HIV-ravimiga, et ravida omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese 1. tüüpi immuunpuudulikkuse viirusega (HIV-1) nakatunud täiskasvanuid.
English: Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine / tenofovir disoproxil)
Estonian: Emtricitabine/Tenofovir disoproxil Zentiva (emtritsitabiin/tenofoviirdisoproksiil)
English: As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Zentiva are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse ravimi Emtricitabine/Tenofovir disoproxil Zentiva kasutamise kohta pidevat järelevalvet.
English: What is Emtricitabine/Tenofovir disoproxil Zentiva and what is it used for?
Estonian: Mis on Emtricitabine/Tenofovir disoproxil Zentiva ja milleks seda kasutatakse?
English: The company that markets Emtricitabine/Tenofovir disoproxil Zentiva will provide an information pack to doctors, which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Zentiva on kidney function, and information about use in adults for pre-exposure prophylaxis.
Estonian: Ravimi Emtricitabine/Tenofovir disoproxil Zentiva turustaja varustab arstid teabepakmega, milles selgitatakse ravimi võimalikku kahjulikku toimet neerutalitlusele ja selle kasutamist täiskasvanutel kokkupuute-eelseks profülaktikaks.
English: Emtricitabine/Tenofovir disoproxil Zentiva contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir.
Estonian: Emtricitabine/Tenofovir disoproxil Zentiva sisaldab kaht toimeainet: nukleosiidset pöördtranskriptaasi inhibiitorit emtritsitabiini ja tenofoviiri, mis on tenofoviirdisoproksiili eelravim.
English: For the treatment of HIV-1 infection, Emtricitabine/Tenofovir disoproxil Zentiva, taken in combination with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: HIV-1 infektsiooni ravis vähendab vähemalt ühe muu HIV-ravimiga koos võetav Emtricitabine/Tenofovir disoproxil Zentiva HIVi kogust veres ja hoiab selle sisalduse väikese.
English: Other information about Emtricitabine/Tenofovir disoproxil Zentiva
Estonian: Muu teave ravimi Emtricitabine/Tenofovir disoproxil Zentiva kohta
English: Emtricitabine/Tenofovir disoproxil Zentiva is also used to help prevent sexually transmitted HIV-1 infection in adults and adolescents who are at high risk of being infected (pre-exposure prophylaxis or PrEP).
Estonian: Ravimit Emtricitabine/Tenofovir disoproxil Zentiva kasutatakse ka sugulisel teel leviva HIV-1 infektsiooni ennetamiseks suure infektsiooniriskiga täiskasvanutel ja noorukitel (kokkupuute-eelne profülaktika).
English: As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Zentiva.
Estonian: Nagu iga ravimi korral, esitas ettevõte ravimi Emtricitabine/Tenofovir disoproxil Zentiva kvaliteedi uuringud.
English: For pre-exposure prophylaxis of HIV-1 infection, it is expected that Emtricitabine/Tenofovir disoproxil Zentiva in the blood will stop the virus from multiplying and spreading from the site of infection in case the individual is exposed to the virus.
Estonian: HIV-1 infektsiooni kokkupuute-eelse ennetamise korral eeldatakse, et viirusega kokkupuutel peatab veres sisalduv Emtricitabine/Tenofovir disoproxil Zentiva viiruse paljunemise ja levimise infektsioonikohast kaugemale.
English: Emtricitabine/Tenofovir disoproxil Zentiva is available as tablets.
Estonian: Ravimit Emtricitabine/Tenofovir disoproxil Zentiva turustatakse tablettidena.
English: Why is Emtricitabine/Tenofovir disoproxil Zentiva authorised in the EU?
Estonian: Miks ravim Emtricitabine/Tenofovir disoproxil Zentiva ELis heaks kiideti?
English: An overview of Emtricitabine/Tenofovir disoproxil Zentiva and why it is authorised in the EU
Estonian: Ülevaade ravimist Emtricitabine/Tenofovir disoproxil Zentiva ja ELis müügiloa väljastamise põhjendus
English: How has Emtricitabine/Tenofovir disoproxil Zentiva been studied?
Estonian: Kuidas ravimit Emtricitabine/Tenofovir disoproxil Zentiva uuriti?
English: Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Estonian: Nii emtritsitabiin kui ka tenofoviir toimivad ühtmoodi, blokeerides pöördtranskriptaasi toime.
English: How is Emtricitabine/Tenofovir disoproxil Zentiva used?
Estonian: Kuidas Emtricitabine/Tenofovir disoproxil Zentiva toimib?
English: Emtricitabine/Tenofovir disoproxil Zentiva can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection.
Estonian: Ravi peab alustama HIV-infektsiooni ravis kogenud arst.
English: 1 Previously known as Nymusa.
Estonian: 1 Varasem nimetus Nymusa.
English: The name of the medicine was changed to Peyona on 24 November 2010.
Estonian: Ravimi nimetus muudeti 24. novembril 2010 Peyonaks.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nymusa on 02 July 2009.
Estonian: Euroopa Komisjon andis Nymusa müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 2. juulil 2009.
English: The solution can also be given by mouth.
Estonian: Lahust tohib manustada ka suu kaudu.
English: What measures are being taken to ensure the safe and effective use of Peyona?
Estonian: Mis meetmed võetakse, et tagada Peyona ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Peyona is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Peyona võimalikult ohutu kasutamine.
English: Other information about Peyona
Estonian: Muu teave Peyona kohta
English: Because caffeine citrate has been used in premature babies for a long time, the company presented information from the scientific literature.
Estonian: Et kofeiintsitraati on enneaegsetel imikutel kasutatud kaua, esitas ettevõte teaduskirjandusest pärinevad andmed.
English: This reduces the effect of adenosine, stimulating the brain to resume breathing.
Estonian: See vähendab adenosiini mõju ja stimuleerib aju hingamist jätkama.
English: Apnoea in premature babies is due to the baby's breathing centres in the brain not being fully developed.
Estonian: Enneaegsetel imikutel tekib apnoe seetõttu, et imiku aju hingamiskeskused ei ole veel täielikult välja arenenud.
English: The doctor will stop treatment with Peyona when the baby has five to seven consecutive days without apnoea attacks.
Estonian: Arst lõpetab ravi Peyonaga, kui imikul ei ole apnoe episoode esinenud 5-7 päeva järjest.
English: This study looked at how long the babies survived and whether or not they had neurological disabilities after 18 months.
Estonian: Uuringus jälgiti imikute elulemust ja neuroloogiliste puuete esinemist 18 kuu pärast.
English: What is Peyona?
Estonian: Mis on Peyona?
English: The CHMP decided that Peyona's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Peyona kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The summary of opinion of the Committee for Orphan Medicinal Products for Peyona can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Peyona kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The full EPAR for Peyona can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Peyona kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Peyona.
Estonian: See on ravimi Peyona Euroopa avaliku hindamisaruande kokkuvõte.
English: Treatment is started with a dose of 20 mg per kilogram bodyweight given once by slow infusion over 30 minutes.
Estonian: Ravi alustatakse annusega 20 mg kehakaalu kilogrammi kohta, manustatuna aeglase infusioonina 30 minuti jooksul.
English: The card will contain information on how Peyona should be administered, including doses, the monitoring of plasma caffeine levels and the side effects that may occur during treatment.
Estonian: Kaart sisaldab teavet Peyona manustamisviisi, sealhulgas annuste, plasma kofeiinisisalduse jälgimise ja ravi ajal ilmneda võivate kõrvalnähtude kohta.
English: Peyona is a solution for infusion (drip) into a vein that contains the active substance caffeine citrate (20 mg/ml).
Estonian: Peyona on infusioonilahus (veeni tilgutatav lahus), mis sisaldab toimeainena kofeiintsitraati (20 mg/ml).
English: Primary means that the apnoea has no obvious cause.
Estonian: „Primaarne” tähendab, et apnoed ei põhjusta ükski teine haigus.
English: The main measure of effectiveness was based on the reduction by at least a half in the daily number of apnoea episodes over ten days.
Estonian: Efektiivsuse põhinäitaja oli apnoe episoodide arvu vähenemine päevas vähemalt poole võrra 10 päeva jooksul.
English: When judged necessary, the doctor may monitor the level of caffeine in the baby's blood and adjust the dose accordingly.
Estonian: Vajaduse korral jälgib arst kofeiini sisaldust imiku veres ja kohandab annust sellele vastavalt.
English: In six out of ten days caffeine citrate was more effective than placebo in reducing the number of apnoea episodes by at least a half.
Estonian: 6 päeval 10st oli kofeiintsitraat efektiivsem kui platseebo apnoe episoodide arvu vähendamisel vähemalt poole võrra.
English: Why has Peyona been approved?
Estonian: Miks Peyona heaks kiideti?
English: In the large published study, 46% of babies given placebo (431 out of 932) died or had neurological disabilities compared with 40% of babies given caffeine citrate (377 out of 937).
Estonian: Ühes ulatuslikus avaldatud uuringus oli nende imikute osakaal, kes surid või kellel ilmnes neuroloogilisi puudeid, platseebot saanud imikute hulgas 46% (431 patsienti 932st) ja kofeiintsitraati saanud imikute hulgas 40% (377 patsienti 937st).
English: In addition, the company that makes Peyona will agree with Member States on a card that will be displayed in intensive care units where the medicine will be used.
Estonian: Lisaks lepib Peyona tootja liikmesriikidega kokku teabekaardi, mis pannakse välja intensiivravi osakondades, kus seda ravimit kasutataks.
English: For more information about treatment with Peyona, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Peyonaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The active substance in Peyona, caffeine citrate, is a stimulant of the nervous system.
Estonian: Peyona toimeaine kofeiintsitraat on närvisüsteemi stimulant.
English: The most common side effects with caffeine citrate (seen in between 1 and 10 patients in 100) are hyperglycaemia (high blood glucose levels), tachycardia (rapid heartbeat) and phlebitis (inflammation of a vein) and inflammation at the site of infusion.
Estonian: Kofeiintsitraadi kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on hüperglükeemia (vere liigne glükoosisisaldus), tahhükardia (südamekloppimine), flebiit (veenipõletik) ja infusioonikoha põletik.
English: Because the number of patients with primary apnoea of premature newborns is low, the disease is considered ‘rare', and Peyona was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 February 2003.
Estonian: Et primaarse apnoega enneaegseid vastsündinuid on vähe ja see haigus esineb harva, nimetati Peyona 17. veebruaril 2003 harvikravimiks.
English: In addition, more babies who were given caffeine citrate had at least eight days with no apnoea: 22% of babies given caffeine citrate compared with none of babies who were given placebo.
Estonian: Samuti oli kofeiintsitraati saanud imikute hulgas rohkem neid, kel ei esinenud apnoed vähemalt 8 päeva: kofeiintsitraati saanud imikute hulgas oli neid 22%, platseebot saanud imikute hulgas mitte ühtegi.
English: What is the risk associated with Peyona?
Estonian: Mis riskid Peyonaga kaasnevad?
English: For the full list of all side effects and restrictions with caffeine citrate, see the package leaflet.
Estonian: Kofeiintsitraadi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Caffeine citrate works in apnoea by blocking the receptors that adenosine normally attaches to.
Estonian: Apnoe esinemisel blokeerib kofeiintsitraat retseptorid, mille külge adenosiin tavaliselt kinnitub.
English: Treatment with the medicine should only take place in an intensive care unit for newborns that is well equipped for monitoring the baby.
Estonian: Ravimit tohib manustada üksnes vastsündinute intensiivravi osakonnas, kus on piisavalt imiku jälgimise seadmeid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Peyona, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Peyona omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Peyona.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: A baby was considered to be in treatment failure if there was no halving of the number of apnoea episodes, if the baby required a machine to assist in breathing or if the baby did not survive.
Estonian: Ülevaates oli efektiivsuse põhinäitaja nende patsientide arv, kelle ravitulemus oli muu kui uuringus määratletud ebaõnnestumine: kui imiku apnoe episoodide arv ei vähenenud poole võrra, kui imik vajas hingamiseks hingamisaparaati või kui imik uuringu ajal suri.
English: In a published study involving 85 premature babies who had had several episodes of apnoea, caffeine citrate was compared with placebo (a dummy treatment).
Estonian: Ühes avaldatud uuringus, milles osales 85 enneaegset imikut, kellel oli esinenud mitu apnoe episoodi, võrreldi kofeiintsitraati platseeboga (näiv ravim).
English: Apnoea in newborns is the cessation of breathing for more than 20 seconds.
Estonian: Vastsündinutel tähendab apnoe hingamiskatkestust, mis kestab kauem kui 20 sekundit.
English: Caffeine citrate is an ‘antagonist' of adenosine, a substance that blocks the activity of some parts of the brain, including the part responsible for controlling breathing.
Estonian: Kofeiintsitraat on teatud ajuosade - muu hulgas ka hingamist juhtiva ajuosa - tegevust blokeeriva aine adenosiini antagonist.
English: In a published review of five studies, caffeine and theophylline (another stimulant) were compared with placebo in 192 premature babies with apnoea.
Estonian: Viie uuringu avaldatud ülevaates võrreldi kofeiini ja teofülliini (samuti stimulant) platseeboga 192 apnoega enneaegsel imikul.
English: How does Peyona work?
Estonian: Kuidas Peyona toimib?
English: Treatment with Peyona should only be started under the supervision of a doctor experienced in treating newborn babies requiring intensive care.
Estonian: Ravi Peyonaga tohib alustada üksnes vastsündinute intensiivravis kogenud arsti järelevalve all.
English: Peyona caffeine citrate
Estonian: kofeiintsitraat
English: What benefit has Peyona shown during the studies?
Estonian: Milles seisneb uuringute põhjal Peyona kasulikkus?
English: In the review of five studies, fewer babies treated with caffeine or theophylline had treatment failure compared with placebo.
Estonian: Viie uuringu ülevaates esines ravi ebaõnnestumist kofeiini- või teofülliiniravi saanud imikute hulgas vähem kui platseebot saanud imikute hulgas.
English: Peyona is used to treat primary apnoea in premature newborns.
Estonian: Peyonat kasutatakse primaarse apnoe raviks enneaegsetel vastsündinutel.
English: How is Peyona used?
Estonian: Kuidas Peyonat kasutatakse?
English: After 24 hours, a ‘maintenance dose' of 5 mg per kg bodyweight may be given everyday
Estonian: 24 tunni pärast võib iga päev manustada säilitusannuse 5 mg kehakaalu kilogrammi kohta aeglase infusioonina 10 minuti jooksul või suu kaudu nasogastraalsondi (ninakaudse maosondi) kaudu.
English: What is Peyona used for?
Estonian: Milleks Peyonat kasutatakse?
English: How has Peyona been studied?
Estonian: Kuidas Peyonat uuriti?
English: A large published study compared caffeine citrate with placebo in treating 2,006 premature babies with apnoea.
Estonian: Ühes ulatuslikus avaldatud uuringus võrreldi kofeiintsitraati platseeboga 2006 enneaegse imiku ravis, kellel esines apnoe.
English: Caffeine citrate was more effective than placebo at treating apnoea in premature babies.
Estonian: Enneaegsete imikute apnoe ravis oli kofeiintsitraat platseebost efektiivsem.
English: This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.
Estonian: See on äärmiselt tähtis, sest kui te võtate korraga rohkem kui ühte ravimit, võib see tugevdada või nõrgendada nende ravimite toimet.
English: • Fever: if you have a temperature of 38°C or greater.
Estonian: • Palavik: kui teil on palavik 38°C või rohkem.
English: • Vomiting: if you vomit more than once in a 24-hour time period.
Estonian: • Oksendamine: kui te oksendate sagedamini kui üks kord 24 tunni jooksul.
English: • Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
Estonian: • Iiveldus: kui teil kaob söögiisu ning iga päev söödud toidu hulk on tunduvalt väiksem kui tavaliselt.
English: Other side effects are:
Estonian: Teised kõrvaltoimed on:
English: Tell your doctor immediately if you experience any of these symptoms.
Estonian: Rääkige koheselt oma arstiga, kui teil esineb mõni nendest sümptomitest.
English: Other side-effects seen in this setting are the following:
Estonian: Teised sellises olukorras täheldatud kõrvaltoimed on järgmised:
English: Rare/Very Rare (Post-Marketing Experience)
Estonian: Harv/väga harv (turuletulekujärgne kogemus)
English: Instead, continue your regular dosing schedule and check with your doctor.
Estonian: Selle asemel jätkake oma tavapärase annustamisskeemiga ja pidage nõu oma arstiga.
English: • blurred or double vision
Estonian: • hägune või topeltnägemine
English: • allergy
Estonian: • allergia
English: DPD deficiency: DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines.
Estonian: DPD vaegus: DPD vaegus on harvaesinev kaasasündinud seisund, millega tavaliselt ei kaasne terviseprobleeme, kui te ei saa teatud ravimeid.
English: Merckle GmbH Ludwig Merckle Str. 3 89143 Blaubeuren Germany
Estonian: Merckle GmbH Ludwig Merckle Str. 3 89143 Blaubeuren Saksamaa
English: Severe and/or Life-threatening (grade 3-4) or considered medically relevant
Estonian: Raske ja/või eluohtlik (raskusaste 3...4) või meditsiiniliselt oluline
English: These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect.
Estonian: Need kõrvaltoimed võivad muutuda tõsisteks; seega on oluline, et kõrvaltoime tekkimisel te alati informeerite otsekohe oma arsti.
English: Pharmacotherapeutic group: antineoplastic agents, antimetabolites, ATC code: L01BC06
Estonian: Farmakoterapeutiline rühm: antineoplastilised ained, antimetaboliidid, ATC-kood: L01BC06
English: 820 Patients were randomised to receive either sequential treatment (n=410) or combination treatment (n=410).
Estonian: 820 patsienti randomiseeriti saama järjestikust ravi (n=410) või kombinatsioonravi (n=410).
English: Cytochrome P-450 2C9 substrates
Estonian: Tsütokroom P450 2C9 substraadid
English: Do not give capecitabine to children and adolescents.
Estonian: Ärge andke kapetsitabiini lastele ja noorukitele.
English: These reactions occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within one month after stopping capecitabine.
Estonian: Need nähud tekkisid mõne päeva kuni mõne kuu jooksul pärast kapetsitabiinravi alustamist ning mõnel juhul ühe kuu jooksul pärast kapetsitabiinravi lõpetamist.
English: Central or peripheral nervous system disease
Estonian: Kesk- või perifeerse närvisüsteemi haigused
English: Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.
Estonian: Käe-jala nahareaktsioon võib viia sõrmejälgede kadumiseni, mis võib mõjutada teie isiku tuvastamist sõrmejälje skaneerimise teel.